194 related articles for article (PubMed ID: 10856791)
1. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge.
Men R; Wyatt L; Tokimatsu I; Arakaki S; Shameem G; Elkins R; Chanock R; Moss B; Lai CJ
Vaccine; 2000 Jul; 18(27):3113-22. PubMed ID: 10856791
[TBL] [Abstract][Full Text] [Related]
2. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge.
Bray M; Men R; Lai CJ
J Virol; 1996 Jun; 70(6):4162-6. PubMed ID: 8648761
[TBL] [Abstract][Full Text] [Related]
3. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
4. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
5. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of molecular strategies to develop a live dengue vaccine.
Lai CJ; Bray M; Men R; Cahour A; Chen W; Kawano H; Tadano M; Hiramatsu K; Tokimatsu I; Pletnev A; Arakai S; Shameem G; Rinaudo M
Clin Diagn Virol; 1998 Jul; 10(2-3):173-9. PubMed ID: 9741643
[TBL] [Abstract][Full Text] [Related]
7. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
[TBL] [Abstract][Full Text] [Related]
8. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection.
Eckels KH; Dubois DR; Summers PL; Schlesinger JJ; Shelly M; Cohen S; Zhang YM; Lai CJ; Kurane I; Rothman A
Am J Trop Med Hyg; 1994 Apr; 50(4):472-8. PubMed ID: 8166355
[TBL] [Abstract][Full Text] [Related]
9. A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis.
Quinan BR; Versiani AF; da Fonseca FG
Vaccine; 2016 Dec; 34(50):6120-6122. PubMed ID: 27817963
[TBL] [Abstract][Full Text] [Related]
10. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
11. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
12. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
13. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
[TBL] [Abstract][Full Text] [Related]
14. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice.
Muné M; Rodríguez R; Ramírez R; Soto Y; Sierra B; Rodríguez Roche R; Marquez G; Garcia J; Guillén G; Guzmán MG
Arch Virol; 2003 Nov; 148(11):2267-73. PubMed ID: 14579183
[TBL] [Abstract][Full Text] [Related]
15. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein.
Chen S; Yu M; Jiang T; Deng Y; Qin C; Qin E
DNA Cell Biol; 2007 Jun; 26(6):361-7. PubMed ID: 17570760
[TBL] [Abstract][Full Text] [Related]
16. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.
Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG
Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289
[TBL] [Abstract][Full Text] [Related]
17. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
[TBL] [Abstract][Full Text] [Related]
18. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.
Velzing J; Groen J; Drouet MT; van Amerongen G; Copra C; Osterhaus AD; Deubel V
Vaccine; 1999 Mar; 17(11-12):1312-20. PubMed ID: 10195766
[TBL] [Abstract][Full Text] [Related]
20. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]